

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/019,048	12/27/2001	Ernst Heinz	0093/000032	5170
26474	7590 01/16/2004		EXAMINER	
KEIL & WEINKAUF			AKHAVAN, RAMIN	
1350 CONNECTICUT AVENUE, N.W. WASHINGTON, DC 20036			ART UNIT	PAPER NUMBER
	,		1636	
			DATE MAIL ED: 01/16/2004	

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)				
Office Action Summany	10/019,048	HEINZ ET AL.				
Office Action Summary	Examiner	Art Unit				
	Ramin (Ray) Akhavan	1636				
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet with the c	orrespondence address				
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statute - Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b). Status	36(a). In no event, however, may a reply be timy within the statutory minimum of thirty (30) days will apply and will expire SIX (6) MONTHS from a cause the application to become ABANDONEI	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133):				
1) Responsive to communication(s) filed on 10 C	October 2003.					
2a) This action is FINAL . 2b) ⊠ This	action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the ments is closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)⊠ Claim(s) <u>1-12</u> is/are pending in the application	☐ Claim(s) 1-12 is/are pending in the application.					
	4a) Of the above claim(s) <u>11 and 12</u> is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.	Claim(s) is/are allowed.					
6)⊠ Claim(s) <u>1-10</u> is/are rejected.						
7) Claim(s) is/are objected to.	Claim(s) is/are objected to.					
8) Claim(s) are subject to restriction and/o	r election requirement.					
Application Papers						
9)⊠ The specification is objected to by the Examiner.						
10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
_ ,	Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).					
11) The oath or declaration is objected to by the Ex	caminer. Note the attached Office	Action or form PTO-152.				
Priority under 35 U.S.C. §§ 119 and 120						
a) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Burea * See the attached detailed Office action for a list	s have been received. s have been received in Application in the second	on No ed in this National Stage				
 13) Acknowledgment is made of a claim for domest since a specific reference was included in the fir 37 CFR 1.78. a) ☐ The translation of the foreign language pro 	st sentence of the specification or ovisional application has been rec	in an Application Data Sheet.				
14) Acknowledgment is made of a claim for domest reference was included in the first sentence of the						
Attachment(s)						
1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal P	(PTO-413) Paper No(s) atent Application (PTO-152)				

Art Unit: 1636

DETAILED ACTION

Election/Restrictions

Applicant's election with traverse of Group I (claims 1-10) in document filed 10/10/2003 is acknowledged. The traversal is on the ground(s) that the special technical feature is SEQ ID No. 1 and its derivatives. This is not found persuasive because Group II is drawn to a product (e.g. linoleic acid), which was previously known in the art. Therefore, no matter what the process for making, such a product cannot share unity of invention with the invention in Group I or III, where the claims are drawn to the particular product. Similarly, having a different use for a product that is already known in the art, does not support the assertion that the different inventions share the same technical feature.

The restriction requirement is still deemed proper and is therefore made FINAL.

Applicant is reminded that non-elected claims must be cancelled. Pursuant to the election made, claims 1-10 are considered for examination.

Specification

The following guidelines illustrate the preferred layout for the specification of a utility application. These guidelines are suggested for the applicant's use.

Arrangement of the Specification

As provided in 37 CFR 1.77(b), the specification of a utility application should include the following sections in order. Each of the lettered items should appear in upper case, without underlining or bold type, as a section heading. If no text follows the section heading, the phrase "Not Applicable" should follow the section heading:

Page 3

- (a) TITLE OF THE INVENTION.
- (b) CROSS-REFERENCE TO RELATED APPLICATIONS.
- (c) STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH OR DEVELOPMENT.
- (d) INCORPORATION-BY-REFERENCE OF MATERIAL SUBMITTED ON A COMPACT DISC (See 37 CFR 1.52(e)(5) and MPEP 608.05. Computer program listings (37 CFR 1.96(c)), "Sequence Listings" (37 CFR 1.821(c)), and tables having more than 50 pages of text are permitted to be submitted on compact discs.) or

REFERENCE TO A "MICROFICHE APPENDIX" (See MPEP § 608.05(a). "Microfiche Appendices" were accepted by the Office until March 1, 2001.)

- (e) BACKGROUND OF THE INVENTION.
 - (1) Field of the Invention.
 - (2) Description of Related Art including information disclosed under 37 CFR 1.97 and 1.98.
- (f) BRIEF SUMMARY OF THE INVENTION.
- (g) BRIEF DESCRIPTION OF THE SEVERAL VIEWS OF THE DRAWING(S).
- (h) DETAILED DESCRIPTION OF THE INVENTION.
- (i) CLAIM OR CLAIMS (commencing on a separate sheet).
- (j) ABSTRACT OF THE DISCLOSURE (commencing on a separate sheet).
- (k) SEQUENCE LISTING (See MPEP § 2424 and 37 CFR 1.821-1.825. A "Sequence Listing" is required on paper if the application discloses a nucleotide or amino acid sequence as defined in 37 CFR 1.821(a) and if the required "Sequence Listing" is not submitted as an electronic document on compact disc).

Claim Objections

1. Claims 1, 4 and 9 are objected to because of the following informalities:

Claim 1 and 9 appear to be missing the *delta* symbol before "6-desaturase". Claim 4 and 9 are Markush-type claims but are improperly phrased using the conjunction "or" instead of the appropriate "and". Appropriate correction is required.

Claim Rejections - 35 USC § 112

The following is a quotation of the second paragraph of 35 U.S.C. 112: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

2. Claims 1-10 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

Claims 1 and 9 are drawn to a process of preparing unsaturated fatty acids, by at least introducing into the organism SEQ ID NO: 1 or derivatives of the same which encode the polypeptide of SEQ ID NO: 2. As written it is unclear if the claims are drawn to derivatives of both SEQ ID NOs: 1 and 2 or only 2; the former includes coding and non-coding regions, while the latter is the polypeptide, therefore the ambiguity is significant. (*See* claims 1(c) and 9(c)). Furthermore, it is unclear whether "enzymatic activity" relates to 6-desaturase activity or some other particularized functionality. Dependent claims are also rejected.

3. Claims 1 and 9 recite the limitation "the enzymatic action". There is insufficient antecedent basis for this limitation in the claim.

The preamble indicates "6-desaturase activity". For the claim to have proper antecedent support, "enzymatic" should be inserted between (i.e. 6-desaturase activity) or enzymatic action should be changed "Δ6-desaturase activity". Dependent claims are also rejected.

Application/Control Number: 10/019,048

Art Unit: 1636

Claim Rejections - 35 USC § 112

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

4. Claims 1-10 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter, which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

Applicant's invention is drawn to a process of preparing unsaturated fatty acids and an organism, where at least one isolated nucleic acid of a sequence encoding 6-desaturase activity is introduced into the organism. Furthermore, the invention is drawn to the same process/organisms where derivatives of SEQ ID NO: 1 and/or SEQ ID NO: 2 having at least 50 percent homology but without a substantial reduction of enzymatic action. In essence, applicant is claiming a genus of sequences while a sufficient representative number of species within the genus have not been disclosed. This is a genus claim in terms of any sequence having at least 50 percent homology to SEQ ID NO: 1 and/or 2.

The written description requirement for a claimed genus may be satisfied by sufficient description of a representative number of species by actual reduction to practice, reduction to drawings or by disclosure relevant identifying characteristics, i.e. structure or other physical and/or chemical properties, by functional characteristics coupled with a known or disclosed correlation between function and structure or by a combination of such identifying characteristics sufficient to show applicant was in possession of the claimed genus.

The specification does not contain any examples of sequences that have said homology and have the prescribed activity. It is acknowledged that claims have a functional limitation, i.e. that the derivative must have a minimal level of $\Delta 6$ -desaturase activity. (Spec. at 10, 11, 44-47). However, merely limiting 50 percent homologous regions to a functional limitation where said sequences have not been clarified, does not meet the written description requirement. Thus the disclosure is not descriptive of the complete structure of a representative number of species, which the claims encompass, as one of ordinary skill in the art cannot envision all homologous sequences having the prescribed function, based on the teachings in the specification. In sum a representative number of species sufficient to convince the skilled artisan that applicant is in possession of the claimed genus has not been disclosed.

Conclusion

All claims are rejected.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Ramin (Ray) Akhavan whose telephone number is 703-305-4454. The examiner can normally be reached on Monday- Friday from 8:00-4:30. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Remy Yucel, Ph.D. can be reached on 703-305-1998. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-0198.

JAMES KETTER
PRIMARY EXAMINER